Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Clinical Trial Data Services supports small to midsize sponsor companies helping them to take the next step towards market approval for their drug or device product.
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Subscribe To Our Newsletter & Stay Updated